UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine ... in combination with inhaled corticosteroids (ICS), so ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback